Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Oksana Koneva
Oksana Koneva

Cost effectiveness and real world efficacy results revealed by Phathom Pharmaceuticals

Cost effectiveness and real world efficacy results revealed by Phathom Pharmaceuticals
Phathom updates GERD treatment data

Phathom Pharmaceuticals released new research data at ACG2026, focusing on its GERD treatment. The data include a cost effectiveness model and analysis of real world patient characteristics and efficacy across BMI subgroups.

The company’s presentation highlights ongoing research to evaluate its therapeutic approach and economic impact in treating GERD. Further updates or peer reviewed publications are expected based on this research.

Phathom Pharmaceuticals recently began screening patients for a Phase 3 clinical trial targeting a new dosing regimen for Non-Erosive GERD, according to an earlier update (see article). This research effort builds on the company’s ongoing pipeline in GERD therapies. Previous disclosures detailed plans to study the regimen’s effectiveness in broader patient groups.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

HSBC’s warning signs point to a bigger risk for global banks
  • By Dmytro Kharkov
  • 36 min ago
HSBC’s warning signs point to a bigger risk for global banks
Editors' Picks
Why do crypto companies want their own banks?
  • By Anastasiia Chabaniuk
  • 19 hours ago
Why do crypto companies want their own banks?
Editors' Picks
Between record and bubble: How Anthropic is approaching its IPO
  • By Mikhail Vnuchkov
  • 23 hours ago
Between record and bubble: How Anthropic is approaching its IPO
Editors' Picks
All Editors' Top Picks

Latest Phathom News

Phathom Pharmaceuticals schedules Q3 2026 earnings release for October 29
  • By Mikhail Vnuchkov
  • 19.10.2026
Phathom Pharmaceuticals schedules Q3 2026 earnings release for October 29
Companies
#Phathom
Phathom Pharmaceuticals initiates Phase 3 trial for new GERD treatment regimen
  • By Pavlo Kot
  • 29.09.2026
Phathom Pharmaceuticals initiates Phase 3 trial for new GERD treatment regimen
Companies
#Phathom
Phathom Pharmaceuticals to present at 2026 Cantor and HCWCO investment conferences
  • By Darina Pashchenko
  • 01.09.2026
Phathom Pharmaceuticals to present at 2026 Cantor and HCWCO investment conferences
Companies
#Phathom
All Phathom News
  • Dmytro Kharkov
  • 36 min ago
HSBC’s warning signs point to a bigger risk for global banks
  • Anastasiia Chabaniuk
  • 19 hours ago
Why do crypto companies want their own banks?
  • Mikhail Vnuchkov
  • 23 hours ago
Between record and bubble: How Anthropic is approaching its IPO
  • Olena Litvinenko
  • Yesterday
From Bitcoin to AI: How crypto companies are reinventing their businesses
  • Eugene Komchuk
  • Yesterday
Trezor security chief: It's easier to trick users than hack a crypto wallet
  • Alena Volkova
  • 9 min ago
Luga coin is mostly used as a gateway to bitcoin in Lugano, Joe Nakamoto notes
  • Igor Krasulya
  • 10 min ago
If SK Hynix can surge on 2028 outlook, Micron could benefit, Jim Cramer notes
  • Elena Nikulina
  • 40 min ago
Ola Electric rose 16 percent on rights issue but trend remains downward, Afzal Lokhandwala notes
  • Mikhail Vnuchkov
  • 1 hour ago
Current crypto market is slow but poised to improve, Sjuul Follings notes
  • Mykhailo Ihnatenko
  • 1 hour ago
People keep missing Bitcoin opportunities, Quinten Francois notes
Top News
  • Pavlo Kot
  • 8 min ago
Moody's assigns A2 and P-1 credit ratings to Ripple's RLUSD stablecoin
Moody's assigns A2 and P-1 credit ratings to Ripple's RLUSD stablecoin
  • Andrey Mastykin
  • 10 min ago
Jio shares jump 21% after IPO, making it India’s second-most valuable company
Jio shares jump 21% after IPO, making it India’s second-most valuable company
  • Dmytro Kharkov
  • 36 min ago
HSBC’s warning signs point to a bigger risk for global banks
HSBC’s warning signs point to a bigger risk for global banks
  • Olga Shendetskaya
  • 1 hour ago
SK Hynix shares surge 11% as record profit lifts Asian chip stocks
SK Hynix shares surge 11% as record profit lifts Asian chip stocks
  • Eugene Komchuk
  • 1 hour ago
Crypto exchange Bithumb suffers cyberattack
Crypto exchange Bithumb suffers cyberattack
Live News
  • Mykhailo Ihnatenko
  • Now
Ethereum price prediction: Can $2,300 support prevent another liquidation wave?
  • Sholanke Dele
  • Now
Galaxy Digital posts $323 million profit and announces $200 million share buyback
  • Ivan Andriyenko
  • Now
Meta draws strong investor interest in $25 billion AI financing deal
  • Parshwa Turakhiya
  • Now
BlackRock teams up with SBI and Startale to advance tokenized finance in Japan
  • Anton Kharitonov
  • Now
EUR/USD remains vulnerable near October lows ahead of central bank decisions
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers